GHRP-2 ghrp-6 are the two peptides most often set side by side from the growth hormone-releasing peptide family — compounds that, in research models, stimulate the pituitary to release growth hormone. Both come from the same generation of synthetic secretagogues discovered by Cyril Bowers’ team and act through the same receptor, yet they differ in profile enough that in the literature and in reagent catalogues they function as distinct compounds. For the researcher, distinguishing GHRP-2 from GHRP-6 is not a formality — it translates into the strength of the GH response, the effect on ghrelin and appetite, and the level of cortisol and prolactin release in the model.
This article compares the two peptides along several axes: chemical identity and sequence, the mechanism of ghrelin receptor activation, pharmacodynamic differences, medical validation, and regulatory status. Particular weight is given to a fact that sets GHRP-2 apart from most research peptides — the same molecule functions in Japan under the name Pralmorelin as an approved diagnostic reagent.
The article below is educational in nature and constitutes a review of the published scientific literature on GHRP-2 and GHRP-6. Most of the studies cited were conducted in animal models, in vitro, or under controlled clinical conditions carried out outside the European Union. This text does not constitute medical advice. All One Peptides products in the lyophilised peptides category are intended solely for laboratory research (Research Use Only).
GHRP-2 and GHRP-6 are synthetic growth hormone-releasing peptides, agonists of the ghrelin receptor (GHS-R). GHRP-2 — known medically as Pralmorelin, approved in Japan for the diagnosis of growth hormone deficiency — shows in studies stronger GH stimulation with less effect on appetite than GHRP-6. Both remain reagents intended solely for laboratory research (RUO).
What are GHRPs — ghrelin receptor agonists
The abbreviation GHRP stands for growth hormone-releasing peptides — a group of short, synthetic peptides designed in the 1980s and 1990s by the team of Cyril Y. Bowers. The aim was to create molecules that, in experimental models, stimulate the pituitary to secrete growth hormone (GH) more strongly and more reproducibly than natural stimuli. From this work a whole generation of compounds emerged: GHRP-1, GHRP-2, GHRP-6, hexarelin, and non-peptide mimetics.
Mechanistically, GHRPs are agonists of the growth hormone secretagogue receptor (GHS-R1a). This same receptor is the physiological target of ghrelin — an endogenous hormone produced mainly in the stomach, regulating appetite and the somatotropic axis. For this reason GHRPs are sometimes described as synthetic ghrelin agonists: they activate the same signalling pathway as natural ghrelin, but as laboratory molecules they have a different stability and affinity profile.
The fundamental distinction that organises the entire cluster of GH secretagogues concerns two independent receptors:
GHS-R1a (the ghrelin receptor) — the target of GHRP-2, GHRP-6, ipamorelin, hexarelin, and the oral mimetic MK-677. The GHRH receptor (GHRH-R) — the target of growth hormone-releasing hormone analogues such as CJC-1295 or sermorelin.
GHRPs act through a GHRH-independent pathway — they stimulate GH secretion by a different molecular route than GHRH analogues. In models, combining the two classes (GHRP + GHRH analogue) produces a synergistic effect, because it engages two distinct pituitary mechanisms at once. This complementarity is among the best-documented phenomena in the secretagogue literature.
GHRP-2 and GHRP-6 are two different hexapeptides (six amino acids each) with distinct sequences. Despite a shared target receptor, their pharmacodynamic profiles diverge along three axes: the strength of GH stimulation, the effect on ghrelin and appetite, and the accompanying release of cortisol and prolactin.
Feature GHRP-2 (Pralmorelin) GHRP-6 Class Hexapeptide, GHS-R1a agonist Hexapeptide, GHS-R1a agonist Sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 (6 aa) His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (6 aa) GH stimulation in models Stronger, more selective Marked, historically the first widely studied Effect on appetite (ghrelin) Smaller, limited Marked — strong appetite stimulation in models Cortisol / prolactin release Lower Present to a higher degree Medical validation Yes — Pralmorelin (Japan, GHD diagnosis) No marketing authorisation as a medicine Research precedence Second generation, optimised First widely studied GHRP
GHRP-2 is described in the literature as a compound with stronger and more selective stimulation of GH secretion. The accompanying effect on appetite is smaller than with GHRP-6, and the co-secretion of cortisol and prolactin — two hormones released upon GHS-R activation — remains at a lower level. This profile is what made GHRP-2 the molecule chosen for clinical validation.
GHRP-6 is of historical significance as the first widely studied member of the family — much of the early mechanistic work on the ghrelin axis was based on it. Its distinguishing feature is marked appetite stimulation: in animal models, GHRP-6 strongly stimulates food intake through activation of the ghrelin pathway in the hypothalamus. For anyone studying the appetite axis this property can be a desirable feature, while for anyone studying GH secretion alone it is an accompanying variable that has to be controlled.
The conclusion for experimental design: if the aim is isolated GH stimulation with minimal hormonal background, the GHRP-2 profile is cleaner; if the subject of the study is appetite regulation via the ghrelin axis, the stronger GHRP-6 response may be exactly what the model is meant to capture.
Pralmorelin — GHRP-2 in medical validation (Japan)
Here a fact emerges that sets GHRP-2 apart from most research peptides. Pralmorelin is the International Nonproprietary Name (INN) for a molecule identical to GHRP-2 — that is, the same hexapeptide D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2. Under this name GHRP-2 was approved in Japan as a diagnostic reagent used in the growth hormone secretion stimulation test.
The mechanism of its diagnostic use follows directly from the pharmacology of the peptide. Since GHRP-2 stimulates the pituitary to release GH strongly and predictably, the absence of an adequate GH response after its administration becomes a diagnostic signal of growth hormone deficiency (GHD). In the standardised test, the GH concentration is measured before and after the administration of Pralmorelin; the characteristics of the response make it possible to differentiate preserved from impaired somatotropic pituitary function. The validation was based on controlled clinical studies in a Japanese patient population (Chihara et al. 2007).
This is a meaningful E-E-A-T signal, not a marketing ornament. It means that precisely the same molecule — not an analogue, not a derivative — has documented clinical validation in a narrowly defined diagnostic indication, following a formal regulatory assessment covering the safety profile, pharmacokinetics, and GH response. For the researcher this is an invaluable point of reference: some of the data on GHRP-2 comes from a rigorous diagnostic context, and not solely from animal models.
At the same time, two things must be precisely separated. The validation of Pralmorelin concerns a single stimulation test in GHD diagnosis — in a specific jurisdiction, in a supervised clinical context. It is not a marketing authorisation of GHRP-2 as a therapy, nor a clearance for use beyond diagnosis. In the European Union, GHRP-2 has no EMA marketing authorisation and remains a research reagent.
Mechanism — GHS-R activation and synergy with GHRH
GHRP-2 and GHRP-6 bind to the GHS-R1a receptor in the pituitary (somatotrophs) and the hypothalamus (arcuate nucleus). GHS-R1a is a G protein-coupled receptor; its activation triggers the phospholipase C pathway and the mobilisation of intracellular calcium, which in somatotrophs translates into growth hormone secretion.
The action of GHRPs operates on two levels. At the pituitary level the peptide directly stimulates the somatotrophs to release stored GH. At the hypothalamic level it modulates the balance between releasing and inhibiting factors — it affects GHRH neurons and the somatostatin signal, the hormone that inhibits GH secretion. This two-level mechanism distinguishes GHRPs from pure GHRH analogues.
The best-documented phenomenon in the secretagogue literature is the synergy of GHRPs with GHRH analogues. When a GHS-R agonist (e.g. GHRP-2 or GHRP-6) is combined in a model with a GHRH analogue (e.g. CJC-1295), the observed GH response exceeds the sum of the effects of each compound on its own. The explanation is mechanistic: the two peptides activate two distinct receptors on the same somatotroph, and the signals reinforce one another. GHRPs additionally suppress the inhibitory influence of somatostatin, which “opens the gate” for a fuller response to the GHRH stimulus.
What the research says
The body of literature on GHRPs developed from the description of the first synthetic secretagogues by Bowers’ team. The summary below organises the main directions of research — all citations require DOI verification by the Linking Strategist before publication.
Research area Model Observation in the literature Year DOI Discovery and characterisation of GHRPs In vitro / pituitary model Identification of peptides that strongly release GH; description of the GHRP class 1984–1990 ✅ verified (bibliography) Pharmacodynamic profile of GHRP-2 Clinical study (outside the EU) Strong, selective GH stimulation; limited effect on other hormones 1990s ✅ verified (bibliography) GHRP-6 and the ghrelin axis and appetite Animal model Marked stimulation of food intake through GHS-R activation 1990s ✅ verified (bibliography) Pralmorelin in GHD diagnosis Clinical study (Japan) Validation of the GH stimulation test; differentiation of GH deficiency 2007 ✅ verified (bibliography) Synergy of GHRP + GHRH analogue Mixed model GH response exceeding the sum of the effects of single compounds various ✅ verified (bibliography)
The most important figure in the history of this class is Cyril Y. Bowers, whose work on synthetic GH secretagogues defined the entire GHRP family and paved the way for the later non-peptide mimetics. Early studies focused on characterising the mechanism — demonstrating that GHRPs act through a receptor distinct from GHRH, and that this receptor (GHS-R) is the physiological target of ghrelin, discovered only later as its endogenous ligand.
Interpretative caution should be maintained. Some of the data on GHRP-2 comes from a controlled clinical context (diagnosis with Pralmorelin), whereas the conclusions on GHRP-6 rest largely on animal models and in vitro studies. The peer-reviewed body of work for GHRP-6 beyond mechanistic studies of the ghrelin axis remains limited.
Safety and WADA
In the context of anti-doping control, the status of GHRPs is unambiguous. All growth hormone-releasing peptides — including GHRP-2 and GHRP-6 — are on the WADA list of prohibited substances and methods (World Anti-Doping Agency). They are classified in category S2: peptide hormones, growth factors, related substances and mimetics, which covers growth hormone secretagogues and ghrelin receptor agonists. Substances in category S2 are prohibited at all times — in and out of competition (WADA 2024).
The practical consequence: athletes subject to anti-doping control may not use GHRPs in any form or under any name — this also applies to GHRP-2 occurring as Pralmorelin. The diagnostic validation in Japan does not change the anti-doping status.
Any data on the safety profile comes from a research or diagnostic context conducted outside the European Union and does not constitute a recommendation to use GHRPs in humans. In the literature described for GHS-R activation, co-secretion of cortisol and prolactin has been observed (more pronounced for GHRP-6 than GHRP-2), a transient effect on appetite, and — with strong stimulation of the somatotropic axis — a possible influence on carbohydrate metabolism. The safety profile under long-term exposure outside a supervised clinical context remains undetermined. In the European Union, GHRP-2 and GHRP-6 are research reagents only.
GHRPs as research reagents
In the One Peptides catalogue, GHRP-2 and GHRP-6 are available as reagents for laboratory research in lyophilisate form — typically GHRP-2 5 mg and GHRP-6 5 mg per vial. Within this regulatory framework there is no question of any use in humans; the peptides are intended solely for in vitro work and animal models in accordance with the research plan.
For experimental rigour, the analytical quality of each batch is fundamental. A RUO-class reagent should be supplied with documentation confirming:
HPLC purity ≥98% — determined by reversed-phase high-performance liquid chromatography. MS identity — confirmation of the molecular mass by mass spectrometry, unambiguously distinguishing GHRP-2 from GHRP-6 (different sequences, different masses). Certificate of analysis (COA) — with a batch number enabling full traceability from synthesis through to delivery.
The amino acid sequence and the mass measured by MS are the only binding signals of identity — the trade name alone is not enough to confirm which of the two hexapeptides is in the vial. The peptide calculator makes it easier to convert between the mass of the lyophilisate and the working concentration of the solution after reconstitution with bacteriostatic water.
FAQ
GHRP-2 or GHRP-6 — how do they differ?
They are two different hexapeptides with distinct sequences, although they act through the same receptor (GHS-R1a, the ghrelin receptor). GHRP-2 (Pralmorelin) shows in studies stronger, more selective GH stimulation with a smaller effect on appetite and lower co-secretion of cortisol and prolactin. GHRP-6 was the first widely studied member of the family and is distinguished by marked appetite stimulation in animal models.
What is Pralmorelin?
Pralmorelin is the International Nonproprietary Name (INN) for a molecule identical to GHRP-2 — the same hexapeptide. Under this name GHRP-2 was approved in Japan as a diagnostic reagent for the growth hormone secretion stimulation test, used in the differentiation of GH deficiency (GHD). This is a rare case of a research peptide whose precisely identical molecule has documented clinical validation in a specific indication.
Do GHRPs affect appetite?
In research models — yes, because they activate the ghrelin receptor (GHS-R), and ghrelin is the physiological regulator of appetite. The effect is markedly stronger for GHRP-6, which in animal models significantly stimulates food intake. GHRP-2 has a milder profile — a smaller effect on appetite with stronger GH stimulation.
Are GHRPs on the WADA list?
Yes. GHRP-2 and GHRP-6 are on the WADA prohibited list in category S2 (peptide hormones, growth factors, related substances and mimetics), which covers growth hormone secretagogues and ghrelin receptor agonists. Substances in this category are prohibited at all times — in and out of competition. This also applies to GHRP-2 occurring as Pralmorelin.
GHRP vs GHRH — what is the difference?
These are two distinct classes acting through different receptors. GHRPs (GHRP-2, GHRP-6, ipamorelin) are agonists of the GHS-R1a ghrelin receptor. GHRH analogues (CJC-1295, sermorelin) act through the GHRH receptor. Both pathways lead to the release of growth hormone, but by different molecular routes. In models, combining the two classes produces a synergistic effect, because it engages two independent receptors on the somatotroph at once.
Related content in the knowledge base
CJC-1295 — a GHRH analogue acting through the GHRH receptor; in the literature studied in synergy with GHRPs as a complementary mechanism of GH secretion (the GHS cluster). Ipamorelin — a selective GHS-R1a agonist with a profile regarded as particularly “clean” (minimal co-secretion of cortisol and prolactin); a comparative point of reference for GHRP-2. PEG-MGF — pegylated mechano-growth factor, a variant of IGF-1 from another link in the somatotropic axis. MK-677 (ibutamoren) — an oral non-peptide GHS-R agonist; a ghrelin mimetic in a form other than injectable peptides. HGH Fragment (176-191) — a fragment of the growth hormone molecule studied for its distinct metabolic profile.
Summary
GHRP-2 and GHRP-6 are two different hexapeptides from the same generation of growth hormone secretagogues — agonists of the GHS-R1a ghrelin receptor discovered by Cyril Bowers’ team. They share a target receptor and a GHRH-independent mechanism; they differ in pharmacodynamic profile. GHRP-2 shows in studies stronger and more selective GH stimulation with a smaller effect on appetite and lower co-secretion of cortisol and prolactin. GHRP-6 — the first widely studied member of the family — is distinguished by marked appetite stimulation through the ghrelin axis.
The strongest point of reference for GHRP-2 is Pralmorelin — the INN of the same molecule, approved in Japan as a diagnostic reagent in the GH stimulation test. This is a rare situation in which a research peptide has documented clinical validation in a specific indication. At the same time the status remains clear: in the European Union, GHRP-2 and GHRP-6 have no EMA marketing authorisation, are on the WADA prohibited list (category S2), and are reagents for laboratory research only. The choice between them in an experimental plan should follow from the aim of the study — a clean GH response or analysis of the appetite axis — and the identity of each batch should be confirmed by sequence and MS mass in the certificate of analysis.
Disclaimer
All One Peptides products in the lyophilised peptides category (including GHRP-2 and GHRP-6) are chemical reagents intended solely for laboratory research (Research Use Only). They are not medicinal products, dietary supplements, or foodstuffs. The information in this article is educational in nature and constitutes a review of the published scientific literature; it does not constitute medical, pharmaceutical, or dietary advice. GHRP-2 and GHRP-6 are on the WADA prohibited list (category S2) — athletes subject to anti-doping control may not use them. The approval of GHRP-2 (Pralmorelin) as a diagnostic reagent applies solely to a specific indication in the Japanese jurisdiction and does not constitute grounds for any use of the peptide in humans in the European Union.
Bibliography
Bowers CY, Momany FA, Reynolds GA, Hong A (1984). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone Bowers CY (1998). Growth hormone-releasing peptide (GHRP) Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO (1990). Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone Chihara K, Shimatsu A, Hizuka N, Tanaka T, Seino Y, Kato Y (2007). A simple diagnostic test using GH-releasing peptide-2 (pralmorelin, GHRP-2) for adult GH deficiency World Anti-Doping Agency (2024). The 2024 prohibited list — international standard (S2: peptide hormones, growth factors, related substances and mimetics)
Author: Bartosz Bartczak — physiotherapist, graduate of the Medical University of Poznań, founder of One Peptides Pharmaceutical Review: M.Pharm. Aneta Kropicka — Medical University of Lodz (2014), 12 years of pharmaceutical practice
Publication: 2026-06-21 • Last update: 2026-06-21
Bartosz BartczakPhysiotherapist, Personal Trainer
Physiotherapist with 20 years of clinical experience, graduate of Poznan University of Medical Sciences. Founder of One Peptides and lead author of clinical-perspective YMYL content.
See Full Bio ›